論文・技術情報追加のお知らせ

1. Exploratory disproportionality analysis of potentially drug-induced eosinophilic pneumonia using United States Food and Drug Administration adverse event reporting system.

薬剤誘発性好酸球性肺炎と関連薬剤の解析

対象DB：FAERS

2. Drugs associated with tachyphylaxis: results from a retrospective pharmacovigilance study using disproportionality analysis.

薬物耐性に関連する薬剤を分析

対象DB：FAERS

3. Post-marketing safety of antiseizure medications: Focus on serious adverse effects including drug reaction with eosinophilia and systemic symptoms (DRESS).

レベチラセタム、クロバザムにDRESSリスク

対象DB：FAERS

4. Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.

レカネマブ、頭痛やARIA-E関連の副作用リスク

対象DB：FAERS

5. Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS).

プロゲステロン系薬剤はうつ症状と関連

対象DB：FAERS

6. A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid.

オベチコール酸の副作用は多く、特にかゆみや疲労が多い

対象DB：FAERS

7. Real world pharmacovigilance assessment of drug related macular degeneration risks.

薬剤性加齢黄斑変性は女性高齢者に多く、特定薬剤が関与

対象DB：FAERS

8. Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses.

DPP-4iとRAAS薬の併用で浮腫リスク増加

対象DB：FAERS

9. Adverse Events Associated with Antivirals for COVID-19: An Analysis Based on FDA Adverse Event Reporting System (FAERS).

パキロビッドは再発、モルヌピラビルは消化器系反応

対象DB：FAERS

10. Hematological toxicities in antibody-drug conjugates related with breast cancer: a pharmacovigilance study using FDA adverse event reporting system database.

ADCは血液毒性を引き起こし、早期発症し致命的な可能性

対象DB：FAERS

11. Safety Evaluation of the Combination with Dexrazoxane and Anthracyclines: A Disproportionality Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database.

デクスラゾキサンはARC軽減効果あり、感染リスク増加

対象DB：FAERS

12. Drug Safety During Breastfeeding: A Comparative Analysis of FDA Adverse Event Reports and LactMed((R)).

授乳中の薬剤の副作用、FAERSとLactMed比較

対象DB：FAERS

13. IL-6R Inhibitors and Gastrointestinal Perforations: A Pharmacovigilance Study and a Predicting Nomogram.

IL-6R阻害薬と消化管穿孔の関連解析

対象DB：FAERS

14. Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database.

GLP-1受容体作動薬に関連する消化器系副作用の解析

対象DB：FAERS

15. Safety assessment of deutetrabenazine: real-world adverse event analysis from the FAERS database.

デュテトラベンジン使用で、舌突進や涎などの新たな副作用が確認

対象DB：FAERS

16. Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data.

MPA使用で新たな副作用、骨痛や虫歯などが確認

対象DB：FAERS

17. An exploratory study evaluated the 30 most commonly reported medications in the United States food and drug administration's adverse event reporting system that are associated with the occurrence of kidney stones.

腎結石と関連のある薬：アタザナビル、トピラマート、プリバシッド

対象DB：FAERS

18. Urotoxicity of Cyclophosphamide: A Comparison Across Neoplastic, Autoimmune, and Transplant Indications.

CYC/IFOの尿路毒性、移植患者で増加、MESNAが保護効果

対象DB：FAERS

19. Autoimmune hepatitis associated with statins: a retrospective study of pharmacovigilance databases and review of the literature.

スタチンと自己免疫性肝炎(AIH)の関連、特にフルバスタチンで顕著

対象DB：FAERS

20. Evaluation of link between COVID-19 adjacent spike in hydroxychloroquine use and increased reports of pemphigus: a disproportionality analysis of the FDA Adverse Event Reporting System.

ヒドロキシクロロキンが天疱瘡発症に関連

対象DB：FAERS

21. Age-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA Adverse Event Reporting System.

クラリスロマイシンの副作用は年齢で異なる

対象DB：FAERS

22. Association of antidepressants with cataracts and glaucoma: a disproportionality analysis using the reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS) pharmacovigilance database.

抗うつ薬は白内障・緑内障のリスクに関連

対象DB：FAERS

23. Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database.

ドロキソパの副作用として新たな感染症や消化器系障害が確認

対象DB：FAERS

24. Comparison of adverse drug reactions of heparin and its derivates in the European Economic Area based on data from EudraVigilance between 2017 and 2021.

ダナパロイドとフォンダパリヌクスの副作用報告率が高い

対象DB：EudraVigilance

25. The Post-Acute COVID-19-Vaccination Syndrome in the Light of Pharmacovigilance.

PACVSは若年層に多く、公式認識が欠如し、社会的・医療的影響が大きい

対象DB：EudraVigilance

26. Age-Dependent Analysis of Suicidal Ideation, Suicide Attempts, and Suicides Associated with SSRI and SNRI Drugs Based on Pharmacovigilance Data.

抗うつ薬は自殺関連ADRが多く、女性や18-64歳での自殺未遂が顕著

対象DB：EudraVigilance

27. Comparative Analyses of the Safety Profiles of Vitamin D Receptor Agonists: A Pharmacovigilance Study Based on the EudraVigilance Database.

VDR作動薬はカルシウム異常や消化器系副作用がある

対象DB：EudraVigilance

28. Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance.

パシレオチドは、血糖上昇や内分泌障害を伴うが、副作用報告は少ない

対象DB：EudraVigilance

29. Do Major Pharmacovigilance Databases Support Evidence of Second Trimester NSAID and Third Trimester Paracetamol Fetotoxicity?

妊娠後期のNSAIDsは心血管・腎毒性リスクが少ない

対象DB：EudraVigilance,VigiBase

30. Cancer-Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK Yellow Card Adverse Drug Reaction (ADR) Reporting.

アレクチニブに心毒性リスクのシグナルが検出された

対象DB：VigiBase

31. Impact of Nurse Staffing Levels on Patient Fall Rates: A Retrospective Cross-Sectional Study in General Wards in Japan.

夜間の看護時間増加で転倒減少、日中は逆効果

対象DB：DPC

32. Comparison between the Outcomes of Pentamidine and Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia in Non-HIV Patients: A Nationwide Japanese Retrospective Cohort Study.

非HIV患者の肺胞性肺炎治療において、ペンタミジンはTMP-SMXより入院死亡率が高い

対象DB：DPC

33. Impact of surgical volume on outcomes of laparoscopic adrenalectomy for benign adrenal tumors: A Japanese nationwide database analysis.

年間手術数が多い施設ほど、腹腔鏡下副腎摘出術の合併症率が低い

対象DB：DPC

34. Periodontal Care Is Associated With a Lower Risk of Dialysis Initiation in Middle-Aged Patients With Type 2 Diabetes Mellitus: A 6-Year Follow-Up Cohort Study Based on a Nationwide Healthcare Database.

T2D患者で歯周治療は透析開始リスクを32-44%低下させる

対象DB：JMDC

35. Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study.

日本の潰瘍性大腸炎患者における5-ASAの1年後の持続率は約56%

対象DB：NDB

36. Comparison of short-term outcomes and perioperative costs in laparoscopic versus robotic surgery for rectal cancers: A real-world cohort study using Japanese nationwide inpatient database.

ロボット手術は短期成績で優れるが、手術費用は高い

対象DB：MDV

37. [Effect of Concomitant Metformin Use on Hematologic Adverse Events in Non-Small-Cell Lung Cancer Patients Undergoing Pemetrexed-Based Chemotherapy: A Study Using a Japanese Claims Database].

メトホルミン併用はペメトレキセド療法での血液毒性リスクに影響なし

対象DB：MDV

38. Causes of death in patients with atrial fibrillation in the UK: a nationwide electronic health record study.

AF患者の死亡原因は循環器疾患が主、SCDリスクは男性で高い

対象DB：CPRD

39. Stroke incidence in heart failure and atrial fibrillation: population cohort study.

HFとAF併存は死亡率が高く、脳卒中リスク過大評価の可能性

対象DB：CPRD

40. Using Quantitative Bias Analysis to Adjust for Misclassification of COVID-19 Outcomes: An Applied Example of Inhaled Corticosteroids and COVID-19 Outcomes.

ICS使用者はCOVID-19入院・死亡リスクが増加

対象DB：CPRD

41. Prevalence and outcomes of patients taking oral corticosteroids for over 1 month undergoing major surgery in England 2010-2020.

手術患者の約3.5%が経口ステロイド使用、死亡率高い

対象DB：CPRD

42. Benzodiazepine and z-drug prescribing in critical care survivors and the risk of rehospitalisation or death due to falls/trauma and due to any cause: a retrospective matched cohort study using the UK Clinical Practice Research Datalink.

ベンゾジアゼピン等は再入院・死亡リスク増加と関連

対象DB：CPRD

43. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes.

SGLT-2阻害薬はDPP-4阻害薬より肝硬変リスクを低減

対象DB：CPRD

44. Treatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population-based cohort study.

膵性糖尿病では、経口薬が有効で、外分泌不全は治療反応の指標となる

対象DB：CPRD